ArticleFrontiers in immunology2026
Neuro-immune-epithelial pathways involving substance P may contribute to mucosal pathology in gastro-oesophageal reflux disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mast Cell-Substance P Neuroimmune Axis in Allergic Contact Dermatitis and Atopic Dermatitis: Molecular Mechanisms and Pathophysiological Perspectives.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Substance P (SP) is contained in nerve fibres innervating the oesophageal mucosa and is released into the mucosa during oesophageal acid perfusion. However, the downstream effects of this peripheral SP are not known. We investigated the expression of SP receptors in the oesophageal mucosa of healthy controls and GORD patients, localisation of mast cells in relation to SP+ nerve fibres, and effects of SP exposure on oesophageal epithelial cells. Methods: Distal oesophageal biopsies were collected from healthy controls (HC; N = 10), functional heartburn (FH; N = 10), non-erosive reflux disease (NERD; N = 14), and erosive reflux disease (ERD; N = 13) patients. IHC was used to determine the cellular expression of the SP receptor, NK1R, on E-Cadherin+, CD3+, and tryptase+ cells. NE-1 oesophageal epithelial cells were incubated with SP to investigate inflammatory pathway activation. The proportion and density of mast cells expressing an SP receptor, MRGPRX2, was analysed, and the distance between SP+ nerve fibres and mast cells was determined. Results: NK1R was expressed on epithelial cells and, rarely, on CD3+ T cells. NK1R fluorescence intensity was significantly higher in NERD and ERD oesophageal mucosa compared with HCs. In NE-1 cells, exposure to SP induced NF-κB phosphorylation, ameliorated by NK1R inhibition, and release of IL-6 and IL-8. In NERD and ERD mucosa, the density of MRGPRX2+ mast cells was significantly higher than HCs. Across all subjects, 25 SP+ nerves were detected; 32% were located within 10 µm of a mast cell, and 84% within 50 µm. Conclusion: Expressions of SP receptors NK1R and MRGPRX2 are upregulated in NERD and ERD oesophageal mucosa, on epithelial cells and mast cells, respectively. Mast cells are also closely apposed to SP+ nerve fibres in the oesophageal mucosa. Furthermore, SP directly induced inflammatory pathway activation and release of cytokines in oesophageal epithelial cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.